Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New online therapy shows promise for migraines after concussion

NCT ID NCT06669780

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an online cognitive-behavioral therapy program for adults who get migraines after a head injury. 83 people with a history of concussion used the program for 12 weeks. The goal was to see if this self-guided digital therapy could reduce headache impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

83 people

The number who actually took part.

Started

Jan 2024

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be aged ≥ 18 to ≤ 70 years * Have a history of concussive TBI ≥ 3 months prior to enrollment: * A concussive TBI is defined by having at least one of the following after a head trauma (ACRM, 1993) oAny period of loss of consciousness; oAny loss of memory for events immediately before or after the accident; oAny alteration in mental state at the time of the accident (e.g., feeling dazed, disoriented, or confused); and oFocal neurological deficit(s) that may or may not be transient oThe injury must not exceed any of the following (ACRM, 1993): * Loss of consciousness of approximately 30 minutes or less; * After 30 minutes an initial GCS score of 13-15; and * PTA not greater than 24 hours * Head trauma resulting in concussive TBI can be due to blast or non-blast mechanisms * Head trauma resulting in concussive TBI can have occurred any time in the participant's life: prior to military service, during deployment, in garrison, or after leaving military service * Have a history of chronic PTH defined as: o Headache is reported to have developed (or worsened) after one of the following\*: * The injury to the head; * Regaining of consciousness following the injury to the head; or * Discontinuation of medication(s) impairing ability to sense or report headache following the injury to the head * Not better accounted for by another ICHD-3 diagnosis\*\* o The headache persists for \>3 months after its onset (ICHD, 2013) * Have a HIT-6™ score of ≥ 56 to 78 indicative of substantial impact (56-59) or severe impact (60-78) on functioning (Yang, Rendas-Baum, Varon, \& Kosinski, 2011) * Be able to provide written, informed consent in English and follow study-related instructions * Have ownership of or reliable access to a smartphone with a data plan or internet connecting capabilities * Be aged ≥ 18 to ≤ 70 years * Have a history of concussive TBI ≥ 3 months prior to enrollment: * A concussive TBI is defined by having at least one of the following after a head trauma (ACRM, 1993): * Any period of loss of consciousness; * Any loss of memory for events immediately before or after the accident; * Any alteration in mental state at the time of the accident (e.g., feeling dazed, disoriented, or confused); and * Focal neurological deficit(s) that may or may not be transient * The injury must not exceed any of the following (ACRM, 1993): * Loss of consciousness of approximately 30 minutes or less; * After 30 minutes an initial GCS score of 13-15; and * PTA not greater than 24 hours * Head trauma resulting in concussive TBI can be due to blast or non-blast mechanisms * Head trauma resulting in concussive TBI can have occurred any time in the participant's life: prior to military service, during deployment, in garrison, or after leaving military service * Have a history of chronic PTH defined as: o Headache is reported to have developed (or worsened) after one of the following\*: * The injury to the head; * Regaining of consciousness following the injury to the head; or * Discontinuation of medication(s) impairing ability to sense or report headache following the injury to the head * Not better accounted for by another ICHD-3 diagnosis\*\* o The headache persists for \>3 months after its onset (ICHD, 2013) * Have a HIT-6™ score of ≥ 56 to 78 indicative of substantial impact (56-59) or severe impact (60-78) on functioning (Yang, Rendas-Baum, Varon, \& Kosinski, 2011) * Be able to provide written, informed consent in English and follow study-related instructions * Have ownership of or reliable access to a smartphone with a data plan or internet connecting capabilities Exclusion Criteria: * They experienced a moderate or severe TBI * Their secondary headache is better accounted for by the ICHD-3 diagnosis of 8.2 medication-overuse headache; must meet diagnostic criteria for at least 1 medication-overuse headache diagnosis (8.2.1-8.2.8) * They are currently engaged in psychotherapeutic treatment or have engaged in psychotherapeutic treatment within 8 weeks prior to trial enrollment (for more information regarding recent treatment in potential participants, see section '3.2 Study Procedures,' sub-section 'Baseline Evaluation') * They report change or discontinuation of headache prophylaxis in the past 4 weeks * They report active psychotic or bipolar symptoms * In the opinion of the investigator, they have other considerations that may adversely affect patient safety, participation, or scientific validity of the data being collected (including, but not limited to, active plan or intent for suicide, visual impairment, hand dysfunction or amputation, substantial cognitive impairment, life expectancy of less than 6 months)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-traumatic headache are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Post-Traumatic Headache

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • 100% Remote Recruitment: Center for Neurscience and Regenerative Medicine

    Bethesda, Maryland, 20817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.